We are pleased to announce that the European Commission has approved a 6-month extension for A-TANGO. This extension compensates for delays caused by the COVID-19 pandemic and enables several critical next steps, including the manufacture of a new batch of study drugs, the opening of additional clinical sites in the United Kingdom, progress toward regulatory approval in Europe (and potentially India), the initiation of patient inclusion in the G-TAK trial (likely starting in April 2026), and the development of a credible scenario for a possible further project extension (ideally 12 more months). The 6-month extension provides renewed momentum to move forward with focus and urgency toward our goal of delivering a much-needed novel therapy for patients with severe alcoholic hepatitis, decompensated cirrhosis, and acute-on-chronic liver failure (ACLF).

Don't miss it! On Wednesday, 26 Nov 2026, 6 pm CET, EASL Studio hosts a new episode titled “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance.” This session will explore the clinical value of rifaximin in the management of hepatic encephalopathy while addressing the growing concerns surrounding antimicrobial resistance - featuring both MICROB-PREDICT's coordinator Jonel Trebicka, as well as A-TANGO's coordinator Rajiv Jalan, together with colleagues Vishal Patel as co-speaker and Debbie Shawcross as moderator.  The EASL Studio episode will be broadcast live and can be accessed here. It will also be available to watch on demand on EASL Campus from Thursday, 27 November.

We are celebrating the completion of the first site visit for A-TANGO's clinical trial: Thanks to huge efforts by Yaqrit and the whole team, we have officially kicked off our Phase 2a trial, evaluating the safety of a novel intravenous TLR-4 antagonist in combination with granulocyte-colony stimulating factor (G-CSF) for the treatment of acute-on-chronic liver failure (ACLF) grades 1 and 2. We call this new combinatorial therapy "G-TAK". This novel therapy offers new hope for liver failure patients and aims to restore some liver functionality and improve patient outcomes. A huge thank you goes out to the Royal Free Hospital, UK, for their warm welcome and dedication to patient-first research. Special recognition goes to the clinical study supervisor Prof. Cornelius Engelmann from the Charité and to Clinical Operations Lead Carrie Morgan from Yaqrit.